DIAMOND trial: Veltassa ® enables patients to achieve long-term potassium control and optimized RAASi therapy
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve long-term potassium control, reduced the risk of recurrent hyperkalemia and prolonged optimized and guideline recommended renin-angiotensin aldosterone system inhibitor (RAASi) therapy. The findings were presented at the 71st Annual Scientific Session & Expo of the American College of Cardiology (ACC) in Washington D.C., U.S.
DIAMOND is the largest interventional study to date for potassium binders investigating the benefits of potassium control in more than 1,000 patients. The trial met its primary and all five key secondary endpoints.
- Treatment with Veltassa® lowered the risk of hyperkalemia events by 37%
- Veltassa® statistically prevented hyperkalemia with more patients being able to maintain Mineralocorticoid Receptor Antagonists (MRA) therapy at target doses compared to placebo
- Patients with chronic kidney disease observed a greater benefit with Veltassa®
- Veltassa® was generally well tolerated and without unexpected safety findings
“We are very encouraged by the full results of the DIAMOND trial which are a milestone for patients suffering from heart failure,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “Data from this trial demonstrated that Veltassa® controlled serum potassium and reduced the risk of recurrent hyperkalemia, while allowing more patients to be treated with guideline recommended, life-saving RAASi therapy.”
“These results are further evidence for the use of potassium binders to optimize heart failure medical therapy,” commented Prof. Javed Butler, Principal Investigator for the DIAMOND study. “RAASi offers significant survival benefits for these patients, but due to risk of hyperkalemia these therapies are unfortunately underutilized in practice. For cases where hyperkalemia is the dominant reason for not giving guideline-directed RAASi therapy, Veltassa® can be an enablement strategy to allow patients to get optimized RAASi therapy while simultaneously lowering the risk of hyperkalemia.”
To date, Veltassa is the only potassium binder studied in placebo-controlled trialsproven to control potassium without compromising RAASi in a variety of patient profiles.
Vifor Pharma continues to support several real world data generation programs with the ongoing phase-IV PLATINUM study and the CARE-HK in HF global registry to evaluate evidence-based care using Veltassa® in chronic kidney disease and heart failure patients. First results on the baseline data and retrospective analyses from CARE-HK in HF are expected in 2022.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com.
About the DIAMOND trial
This prospective phase-III multicenter, double-blind, randomized withdrawal, placebo-controlled trial was designed to evaluate the potential role of Veltassa® in enabling patients with, or at high risk of, hyperkalemia to remain on RAASi therapy. DIAMOND is the largest interventional study for potassium binders assessing control of serum potassium, hyperkalemia events, and enablement of RAASi in heart failure patients with reduced ejection fraction and hyperkalemia in more than 1,000 patients. On recommendation of the independent study Executive Committee and due to COVID-19 impact on recruitment, the primary endpoint has been changed in June 2021 to investigate the role of Veltassa® in controlling serum potassium, preventing hyperkalemia and maintain RAASi use in heart failure patients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact and further information:
Global Head Corporate Communications
+41 79 957 96 73
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Innovative AI software for the detection of pancreatic diseases: first-in-human application successful16.5.2022 14:21:00 CEST | Press release
Diseases of the pancreas can have serious consequences for patients and are difficult to diagnose. Early detection is crucial for the patient's chance of survival. In Europe today, more than 90 percent of patients die of pancreatic cancer within the first five years after diagnosis. The Medi-Globe Group, a leading international MedTech company based in Achenmühle, Bavaria, will, in cooperation with the French Institut Hospitalo-Universitaire (IHU) Strasbourg, develop the world's first AI software for the detection of diseases of the pancreas in endoscopic ultrasound (EUS) examination. The key technology here is artificial intelligence. As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005559/en/ The new AI software has the potential to revolutionize t
Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences16.5.2022 14:00:00 CEST | Press release
Apollo (NYSE: APO) and Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a long-term strategic and financial partnership. Under the agreement, Apollo will take a minority equity interest in Sofinnova and commit up to €1 billion of managed capital to its investment funds. This strategic partnership is poised to significantly accelerate Sofinnova’s growth. For Apollo, the investment will meaningfully increase its presence in life sciences and contribute to its growth ecosystem of partners that bring specialized knowledge and networks to its integrated platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005254/en/ Together, Sofinnova and Apollo will offer entrepreneurs a more comprehensive range of capital solutions to help bring new therapeutic and biotechnology-based solutions to the market. The commitment to invest up to €1 bi
KAUST Spins-in Five Cutting-Edge International Startups and Brings New Tech to Saudi Arabia16.5.2022 13:42:00 CEST | Press release
King Abdullah University of Science and Technology (KAUST) has recently wrapped up 'Destination Deep Tech,' a Saudi-first program that spins in leading-edge global startups to the Kingdom to develop deep tech innovations. The international startups - CeEntek, Hopu, Insignes-Labs, Pasqal, and Proteinea - were chosen to experience the three-month program as a result of their highly advanced technology expansion into the MENA region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005518/en/ The founders of the 5 international startups CeEntek, Hopu, Insignes-Labs, Pasqal, and Proteinea at KAUST (Photo: AETOSWire) “KAUST is the Deep Tech Heart of the Saudi Economy, and so we are delighted to welcome these talented international startups to KAUST and the Kingdom as part of Destination Deep Tech,” said Dr. Kevin Cullen, Vice President of KAUST Innovation. Pasqal, from France, is a leading European Quantum Computing startup t
QCT Delivers on the 5G Promise with Innovative Edge Infrastructures and 5G Solutions16.5.2022 13:00:00 CEST | Press release
Quanta Cloud Technology (QCT), a leading data center hardware solution provider, today announced details around its participation at the Big 5G Event 2022, being held onsite from May 16 – May 18, at the Austin Convention Center in Austin, Texas. QCT will showcase 5G infrastructure and solution demos at Booth #300 for both public and private networks and share their latest insights at the event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005006/en/ (Graphic: Business Wire) To support the ever-growing compute and networking needs at the telco edge, QCT showcases its latest QuantaEdge products and solutions powered by Intel Xeon-SP and Xeon-D processors, spanning carrier grade 5G systems, edge servers and radio units that are cloud native to deliver maximum deployment flexibility. QCT demo highlights include: QuantaEdge EGD33B-WT - a next-gen outdoor pole-mount edge server designed for vRAN/MEC use cases, featuring a
Solynta and Incotec Announce Partnership to Optimize Performance of Hybrid True Potato Seeds16.5.2022 12:00:00 CEST | Press release
Hybrid potato innovator Solynta and seed enhancement company Incotec have entered in a collaboration agreement. By combining forces, the group will bring world-class seed technology and elite genetics to potato farmers worldwide. Solynta is a Netherlands-based company using hybrid potato breeding to grow a more sustainable future. Solynta has developed a unique portfolio of hybrid potato varieties for farmers that are dependable, productive and resilient to climate change. Incotec, a global seed enhancement company, has developed technologies including a new pelletization method and seed priming formula specifically tailored for true potato seeds. This seed technology will allow Solynta’s true potato seeds to succeed in diverse growing environments. Johan Trouw, Solynta Supply Chain Director and co-founder, noted, “At Solynta, we believe that partnering with industry leaders like Incotec supports our mission of creating solutions for food and nutritional insecurity. Their expertise in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom